Harlan Pinto | Stanford Medicine

Dr. Harlan A. Pinto

Claim this profile

VA Palo Alto Health Care System

Studies Cancer
Studies Pancreatic Cancer
11 reported clinical trials
54 drugs studied

Area of expertise

1Cancer
Harlan A. Pinto has run 5 trials for Cancer. Some of their research focus areas include:
Stage IV
KRAS positive
Stage III
2Pancreatic Cancer
Harlan A. Pinto has run 4 trials for Pancreatic Cancer. Some of their research focus areas include:
KRAS positive
Stage IV
BRAF positive

Affiliated Hospitals

Image of trial facility.
VA Palo Alto Health Care System

Clinical Trials Harlan A. Pinto is currently running

Image of trial facility.

Pre-Surgery Chemotherapy + Surgery & Radiation

for Sinus Cancer

This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation.
Recruiting1 award Phase 2
Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria

More about Harlan A. Pinto

Clinical Trial Related8 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Harlan A. Pinto has experience with
  • Cisplatin
  • Binimetinib
  • Carboplatin
  • Bevacizumab
  • Ipatasertib
  • Docetaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Harlan A. Pinto specialize in?
Is Harlan A. Pinto currently recruiting for clinical trials?
Are there any treatments that Harlan A. Pinto has studied deeply?
What is the best way to schedule an appointment with Harlan A. Pinto?
What is the office address of Harlan A. Pinto?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security